Post by Johnson & Johnson Innovative Medicine ANZ

The Pharmaceutical Benefits Advisory Committee (PBAC) is reviewing RYBREVANT® (amivantamab), a targeted therapy, in combination with chemotherapy for people with advanced EGFR-positive non-small cell lung cancer (NSCLC) whose initial treatment has stopped working. PBAC wants to hear from patients, carers, families, and healthcare professionals about the real impact of lung cancer. Your input can help guide decisions on whether RYBREVANT should be funded through the Pharmaceutical Benefits Scheme (PBS). Submissions are confidential.  Takes about 10 minutes to complete. Share your experience here by 21 January 2026: https://lnkd.in/gRmKsNMb Please review the RYBREVANT Consumer Medicine Information (CMI) for more information about this therapy, including risks, precautions, and common side effects such as skin rash, paronychia (infection of the skin around a fingernail or toenail), infusion-related reaction, and fatigue. https://ap-jc.com/cmi

Video Content